Total Payments
$4.1M
2024 Payments
$763,204
Companies
49
Transactions
4,412
Medicare Patients
17,080
Medicare Billing
$1.7M
Payment Breakdown by Category
Other$3.0M (71.4%)
Consulting$516,623 (12.5%)
Travel$429,797 (10.4%)
Research$166,376 (4.0%)
Food & Beverage$69,610 (1.7%)
Education$892.43 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.9M | 882 | 70.9% |
| Consulting Fee | $516,623 | 190 | 12.5% |
| Travel and Lodging | $429,797 | 1,198 | 10.4% |
| Unspecified | $166,376 | 124 | 4.0% |
| Food and Beverage | $69,610 | 1,991 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $13,240 | 1 | 0.3% |
| Honoraria | $8,831 | 4 | 0.2% |
| Education | $892.43 | 22 | 0.0% |
Payments by Type
General
$4.0M
4,288 transactions
Research
$166,376
124 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $841,620 | 848 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $647,794 | 553 | $0 (2024) |
| Lilly USA, LLC | $621,737 | 705 | $0 (2024) |
| GENZYME CORPORATION | $614,438 | 470 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $256,853 | 187 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $237,266 | 306 | $0 (2024) |
| Dermavant Sciences, Inc. | $174,243 | 165 | $0 (2024) |
| UCB, Inc. | $171,152 | 209 | $0 (2024) |
| Incyte Corporation | $150,632 | 136 | $0 (2024) |
| Eli Lilly and Company | $120,254 | 98 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $763,204 | 653 | GENZYME CORPORATION ($157,979) |
| 2023 | $825,024 | 799 | ABBVIE INC. ($123,798) |
| 2022 | $658,959 | 718 | ABBVIE INC. ($155,012) |
| 2021 | $410,093 | 505 | AbbVie Inc. ($117,755) |
| 2020 | $250,656 | 293 | Lilly USA, LLC ($95,924) |
| 2019 | $400,460 | 540 | AbbVie, Inc. ($98,138) |
| 2018 | $448,041 | 469 | Regeneron Healthcare Solutions, Inc. ($114,716) |
| 2017 | $385,952 | 435 | AbbVie, Inc. ($121,191) |
All Payment Transactions
4,412 individual payment records from CMS Open Payments — Page 1 of 177
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $57.23 | General |
| 12/19/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $27.83 | General |
| Category: DERMATOLOGY | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: IMMUNOLOGY | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Immunology | ||||||
| 12/17/2024 | UCB, Inc. | Bimzelx (Biological) | Travel and Lodging | Cash or cash equivalent | $13.40 | General |
| Category: Immunology | ||||||
| 12/17/2024 | PFIZER INC. | EUCRISA (Drug), CIBINQO, LITFULO | Food and Beverage | In-kind items and services | $2.16 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 12/16/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $562.98 | General |
| 12/16/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: DERMATOLOGY | ||||||
| 12/15/2024 | Lilly USA, LLC | EBGLYSS (Drug) | Food and Beverage | In-kind items and services | $15.62 | General |
| Category: Immunology | ||||||
| 12/14/2024 | ABBVIE INC. | RINVOQ (Biological) | Travel and Lodging | In-kind items and services | $489.54 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,200.00 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $1,004.16 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $527.42 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $471.81 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $324.58 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $262.21 | General |
| Category: Immunology | ||||||
| 12/12/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $121.37 | General |
| Category: Immunology | ||||||
| 12/12/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $28.93 | General |
| Category: DERMATOLOGY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $583.89 | General |
| Category: Immunology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $490.45 | General |
| Category: Immunology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $417.52 | General |
| Category: Immunology | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Travel and Lodging | Cash or cash equivalent | $204.19 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| H15-457 | AbbVie, Inc. | $30,703 | 14 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $26,752 | 5 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $13,339 | 4 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $12,540 | 8 |
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF LY2439821 TO ETANERCEPT AND PLACEBO IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $11,890 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $11,742 | 14 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $7,186 | 1 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,304 | 15 |
| AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $6,199 | 16 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $4,187 | 3 |
| Lamellar Ichthyosis Phase II Study | Mayne Pharma Inc. | $4,000 | 1 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $3,153 | 6 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $3,003 | 4 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,785 | 6 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,396 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3375880 IN ADULT SUBJECTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: THE ADMIRE STUDY | Eli Lilly and Company | $2,380 | 2 |
| AN OPEN-LABEL STUDY OF DUPILUMAB IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS DUPILUMAB CLINICAL TRIALS | Regeneron Pharmaceuticals, Inc. | $2,298 | 7 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,064 | 3 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $1,971 | 3 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $1,516 | 3 |
| CC-10004-PSOR-012 | Celgene Corporation | $1,251 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 1 |
| CC-10004-PSOR-012 - A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis | Celgene Corporation | $967.00 | 1 |
| Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients 6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL) | GENZYME CORPORATION | $500.00 | 1 |
| A Phase 2 3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged 6 Months to 6 Years With Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $296.44 | 1 |
| EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) | Eli Lilly and Company | $104.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 3,829 | 6,352 | $1.4M | $352,959 |
| 2022 | 24 | 4,304 | 7,307 | $1.7M | $402,675 |
| 2021 | 32 | 5,156 | 9,030 | $2.1M | $549,376 |
| 2020 | 29 | 3,791 | 6,317 | $1.2M | $400,957 |
Total Patients
17,080
Total Services
29,006
Medicare Billing
$1.7M
Procedure Codes
109
All Medicare Procedures & Services
109 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 994 | 1,324 | $393,228 | $96,867 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 352 | 472 | $198,240 | $49,273 | 24.9% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 710 | 911 | $203,153 | $42,962 | 21.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 435 | 479 | $161,902 | $42,004 | 25.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 170 | 188 | $71,064 | $19,363 | 27.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 187 | 187 | $69,003 | $16,284 | 23.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 491 | 2,214 | $50,922 | $13,583 | 26.7% |
| 13121 | Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | Office | 2023 | 31 | 33 | $46,695 | $12,977 | 27.8% |
| 13101 | Complicated repair of wound of trunk, 2.6-7.5 cm | Office | 2023 | 26 | 26 | $34,398 | $9,527 | 27.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 120 | 173 | $29,064 | $8,344 | 28.7% |
| 13132 | Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | Office | 2023 | 15 | 15 | $23,520 | $6,592 | 28.0% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 33 | 48 | $28,512 | $6,156 | 21.6% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 41 | 43 | $17,931 | $4,724 | 26.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 34 | 34 | $18,598 | $4,459 | 24.0% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 21 | 22 | $12,364 | $3,554 | 28.7% |
| 11602 | Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 26 | 27 | $21,951 | $3,257 | 14.8% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 20 | 21 | $8,799 | $2,546 | 28.9% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 14 | 14 | $8,974 | $2,200 | 24.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 39 | 41 | $7,626 | $2,081 | 27.3% |
| 11603 | Removal of cancer skin growth of body, arms, or legs, 2.1-3.0 cm | Office | 2023 | 15 | 15 | $13,905 | $1,982 | 14.3% |
| 69100 | Biopsy of ear | Office | 2023 | 20 | 20 | $6,420 | $1,523 | 23.7% |
| 13122 | Complicated repair of wound of scalp, arms, or legs, each additional 5.0 cm or less | Office | 2023 | 12 | 12 | $5,076 | $1,440 | 28.4% |
| 11402 | Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 11 | 11 | $6,292 | $985.08 | 15.7% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 22 | $1,034 | $275.94 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,170 | 1,663 | $490,585 | $119,983 | 24.5% |
About Dr. Benjamin Lockshin, MD
Dr. Benjamin Lockshin, MD is a Dermatology healthcare provider based in Silver Spring, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275523110.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Benjamin Lockshin, MD has received a total of $4.1M in payments from pharmaceutical and medical device companies, with $763,204 received in 2024. These payments were reported across 4,412 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.9M).
As a Medicare-enrolled provider, Lockshin has provided services to 17,080 Medicare beneficiaries, totaling 29,006 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 109 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Silver Spring, MD
- Active Since 10/23/2005
- Last Updated 03/12/2014
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1275523110
Products in Payments
- DUPIXENT (Biological) $854,899
- TALTZ (Drug) $461,682
- SKYRIZI (Biological) $362,769
- COSENTYX (Biological) $228,958
- DUPIXENT DUPILUMAB INJECTION (Biological) $211,169
- Sotyktu (Drug) $210,823
- Humira (Biological) $195,045
- RINVOQ (Biological) $181,700
- VTAMA (Drug) $157,539
- OPZELURA (Drug) $146,490
- DUPIXENT (Drug) $117,451
- Bimzelx (Biological) $95,453
- Zoryve (Drug) $75,959
- Skyrizi (Biological) $70,254
- OLUMIANT (Drug) $59,490
- Cimzia (Drug) $31,396
- Olumiant (Drug) $30,667
- ATOPIC DERMATITIS - DISEASE (Drug) $24,853
- ADBRY (Biological) $23,118
- CIBINQO (Drug) $20,244
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Silver Spring
Dr. Amy Cole, Md, MD
Dermatology — Payments: $15,910
Dermatology $15,910
Dr. Eleanor Ford, Md, MD
Dermatology — Payments: $4,364
Dermatology $4,364
Dr. Norman Lockshin, Md, MD
Dermatology — Payments: $3,753
Dermatology $3,753
Kavita Goyal, M.d, M.D
Dermatology — Payments: $1,414
Dermatology $1,414
Michelle Levender, Md, MD
Dermatology — Payments: $1,410
Dermatology $1,410
Edward Cowen, M.d, M.D
Dermatology — Payments: $762.26
Dermatology $762.26